Completed PHASE2 INTERVENTIONAL 1-arm NCT02537054

Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE) (EyNeP)

Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)

Sponsor: University Hospital, Bonn

Conditions Pseudoxanthoma Elasticum

Interventions Aflibercept

Updated 6 times since 2017 Last updated: May 5, 2019 Started: Sep 30, 2015 Primary completion: Jul 2, 2018 Completion: Jul 2, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02537054, this PHASE2 trial focuses on Pseudoxanthoma Elasticum and remains completed. Sponsored by University Hospital, Bonn, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Jun 2019 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Bonn

Data source: University Hospital, Bonn

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bonn, Germany